WuXi XDC Cayman, Inc. (HK:2268)
:2268
Top Page
WuXi XDC Cayman, Inc.
(2268)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$67.00
▲(9.57% Upside)
Action:UpgradedDate:10/11/25
WuXi XDC Cayman, Inc. benefits from strong financial performance and positive technical indicators. However, the high P/E ratio and negative free cash flow are notable concerns. The absence of earnings call and corporate events data limits further insights.
Positive Factors
Strong Revenue Growth
A 90.8% revenue increase indicates rapidly expanding demand for WuXi XDC's CDMO services and successful client wins. Sustained high topline growth supports scale advantages, amortization of fixed costs, reinvestment in capacity and R&D, and strengthens long-term competitive positioning.
Negative Factors
Negative Free Cash Flow
Large negative free cash flow driven by heavy capex reduces unencumbered liquidity and may force reliance on external financing. If sustained, this constrains dividend or buyback capacity and increases execution risk if revenue growth or margin levels decelerate.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
A 90.8% revenue increase indicates rapidly expanding demand for WuXi XDC's CDMO services and successful client wins. Sustained high topline growth supports scale advantages, amortization of fixed costs, reinvestment in capacity and R&D, and strengthens long-term competitive positioning.
Read all positive factors
WuXi XDC Cayman, Inc. (2268) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$76.93B
Dividend YieldN/A
Average Volume (3M)6.66M
Price to Earnings (P/E)46.0
Beta (1Y)1.13
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees2,041
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.69
Shares Outstanding1,257,992,700
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.20
Price to Sales (P/S)8.51
P/FCF Ratio-43.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$83.23Price Target Upside36.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.63
Revenue Forecast (FY)HK$8.09B
WuXi XDC Cayman, Inc. Business Overview & Revenue Model
Company Description
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufac...
How the Company Makes Money
WuXi XDC generates revenue primarily through its contract development and manufacturing services, which are provided to pharmaceutical and biotechnology companies. The company charges fees for various services including research and development, c...
WuXi XDC Cayman, Inc. Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.09B | 4.05B | 2.12B | 990.42M | 311.13M | 96.35M |
| Gross Profit | 1.68B | 1.24B | 559.56M | 261.08M | 113.49M | 8.08M |
| EBITDA | 1.42B | 1.33B | 420.28M | 151.75M | 77.37M | 7.10M |
| Net Income | 1.33B | 1.07B | 283.54M | 155.73M | 54.93M | 26.30M |
Balance Sheet | ||||||
| Total Assets | 10.62B | 9.12B | 6.74B | 2.50B | 879.75M | 408.47M |
| Cash, Cash Equivalents and Short-Term Investments | 4.54B | 3.97B | 4.05B | 734.97M | 26.32M | 28.39M |
| Total Debt | 1.04B | 496.43M | 2.84M | 77.18M | 24.59M | 0.00 |
| Total Liabilities | 3.18B | 2.48B | 1.28B | 1.02B | 858.87M | 32.79M |
| Stockholders Equity | 7.44B | 6.64B | 5.45B | 1.48B | 20.88M | 375.68M |
Cash Flow | ||||||
| Free Cash Flow | -99.81M | -787.95M | -206.51M | 50.43M | 7.23M | -32.03M |
| Operating Cash Flow | 1.54B | 717.22M | 332.85M | 251.82M | 59.14M | 20.85M |
| Investing Cash Flow | -5.00B | -3.33B | -91.23M | -1.28B | -51.59M | -52.42M |
| Financing Cash Flow | 967.91M | 475.36M | 3.52B | 1.33B | 22.34M | 69.12M |
WuXi XDC Cayman, Inc. Technical Analysis
Positive
61.15
Price Trends
60.83
Positive
64.28
Negative
62.28
Negative
Market Momentum
-0.36
Negative
55.79
Neutral
88.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2268, the sentiment is Positive. The current price of 61.15 is above the 20-day moving average (MA) of 56.71, above the 50-day MA of 60.83, and below the 200-day MA of 62.28, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 55.79 is Neutral, neither overbought nor oversold. The STOCH value of 88.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2268.
WuXi XDC Cayman, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | HK$337.15B | 13.23 | 23.81% | 1.84% | 11.55% | 64.46% | |
73 Outperform | HK$76.93B | 46.00 | 19.62% | ― | ― | ― | |
66 Neutral | HK$28.72B | 46.26 | 3.65% | 0.15% | -21.76% | ― | |
58 Neutral | HK$47.82B | 37.05 | 2.95% | 0.80% | -3.81% | -34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2268
WuXi XDC Cayman, Inc.
61.15
31.35
105.20%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
42.70
18.40
75.70%
HK:2359
WuXi AppTec Co., Ltd. Class H
124.90
75.20
151.31%
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
21.22
11.02
108.04%
WuXi XDC Cayman, Inc. Corporate Events
WuXi XDC Schedules Board Meeting to Approve 2025 Annual Results
Jan 23, 2026
WuXi XDC Cayman Inc., incorporated in the Cayman Islands and listed in Hong Kong, announced that its board of directors will convene on 23 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2...
WuXi XDC Signals Strong 2025 Earnings with Double-Digit Profit Growth
Jan 14, 2026
WuXi XDC Cayman Inc. has issued a positive profit alert, indicating that based on preliminary unaudited figures for 2025, the group expects strong growth across key financial metrics. Revenue for the year to 31 December 2025 is projected to rise b...
Citigroup-Backed Offeror Launches Premium Takeover Bid for WuXi XDC
Jan 14, 2026
Citigroup Global Markets Asia Limited, on behalf of an offeror, has launched a voluntary conditional cash offer to acquire all issued shares of WuXi XDC Cayman, Inc. not already owned by the offeror and its concert parties, as well as to cancel al...
WuXi XDC Highlights Strong 2025 Pipeline and Expansion Plans Ahead of J.P. Morgan Healthcare Conference
Jan 14, 2026
WuXi XDC Cayman Inc. announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in January 2026, using the event to share detailed information on its business operations with investors while simultaneously disclosing the s...
WuXi XDC Cayman Inc. Secures Shareholder Approval for Strategic Agreements
Dec 12, 2025
WuXi XDC Cayman Inc. announced the successful passing of all proposed resolutions at its extraordinary general meeting held on December 12, 2025. These resolutions included the approval of revised service fees and new master services agreements wi...
WuXi XDC Cayman Inc. Announces Extraordinary General Meeting for Strategic Resolutions
Nov 25, 2025
WuXi XDC Cayman Inc. has announced an extraordinary general meeting to be held on December 12, 2025, to discuss and approve several resolutions related to service agreements with WuXi Biologics and WuXi AppTec. These resolutions include revised ma...
WuXi XDC Cayman Inc. Updates on Continuing Connected Transactions
Nov 25, 2025
WuXi XDC Cayman Inc., a company incorporated in the Cayman Islands, has announced revisions to its annual caps for relevant Continuing Connected Transactions (CCT) agreements, the renewal of existing CCT agreements, and the introduction of new CCT...
WuXi XDC Announces EGM for Key Service Agreement Approvals
Nov 25, 2025
WuXi XDC Cayman Inc. has announced the closure of its register of members in anticipation of an extraordinary general meeting (EGM) scheduled for December 12, 2025. This meeting will allow independent shareholders to vote on the revision and renew...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.